ArticlePharmaceutics2021

Development, Characterization, and In Vivo Evaluation of a Novel Aptamer (Anti-MUC1/Y) for Breast Cancer Therapy.

Huma Khan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.